电子知情同意——COVID-19疫情期间维持临床试验招募的指南
本文描述NeuroSAFE PROOF随机临床试验在COVID-19疫情招募暂停后,基于REDCap环境建立远程电子知情同意框架的实施过程、对招募速度的影响及患者体验。实施后尽管经历第二次封锁,仍入组63例新患者(每月4例),而面对面咨询受限下旧方法无法招募;患者反馈积极,所需故障排除有限。该路径符合知情同意的伦理与监管要求,可帮助研究者在疫情不确定期整合电子知情同意。
要点
- 基于REDCap建立远程电子知情同意框架,内容参照已批准的纸质知情同意书。
- 电子知情同意免除面对面会面,但仍通过在线互动进行咨询并提供远程支持。
- 实施前判定整个流程符合监管要求,实施后患者反馈积极、故障排除需求有限。
核心结论
- 远程电子知情同意招募对NeuroSAFE PROOF试验在COVID-19疫情期间得以继续至关重要。
- 所描述的路径符合知情同意的伦理与监管指南,同时尽量减少增加COVID-19传播风险的面对面互动。
- 该指南将帮助研究者在疫情走向不确定期间将电子知情同意整合入进行中或计划中的临床试验。
研究设计与样本
- NeuroSAFE PROOF试验为随机临床试验,评估机器人辅助根治性前列腺切除术(RARP)中冰冻切片分析的作用。
- 对方案进行实质性修订,基于REDCap环境创建远程电子知情同意框架,结构及内容参照已批准的纸质知情同意书。
- 电子知情同意免除面对面会面,但仍通过在线互动进行咨询,并通过远程会诊提供持续支持。
- 整个流程在实施前经判定符合监管要求。
主要发现
- 首次招募暂停前,NeuroSAFE PROOF平均每月招募9例患者。
- 电子知情同意实施后,尽管经历第二次封锁,仍入组63例新患者(每月4例),若采用旧方法在面对面咨询受限下这些患者均无法被招募。
- 患者对该平台的使用给出积极反馈。
- 实施后所需故障排除有限。
临床怎么用
- 作者描述该远程电子知情同意路径符合知情同意的伦理与监管指南,同时尽量减少增加COVID-19传播风险的面对面互动。
- 作者认为该指南将帮助研究者在疫情走向不确定期间将电子知情同意整合入进行中或计划中的临床试验。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The COVID-19 pandemic has posed daunting challenges when conducting clinical research. Adopting new technologies such as remote electronic consent (e-Consent) can help overcome them. However, guidelines for e-Consent implementation in ongoing clinical trials are currently lacking. The NeuroSAFE PROOF trial is a randomized clinical trial evaluating the role of frozen section analysis during RARP for prostate cancer. In response to the COVID-19 crisis, recruitment was halted, and a remote e-Consent solution was designed. The aim of this paper is to describe the process of implementation, impact on recruitment rate, and patients' experience using e-Consent. METHODS: A substantial amendment of the protocol granted the creation of a remote e-Consent framework based on the REDCap environment, following the structure and content of the already approved paper consent form. Although e-Consent obviated the need for in-person meeting, there was nonetheless counselling sessions performed interactively online. This new pathway offered continuous support to patients through remote consultations. The whole process was judged to be compliant with regulatory requirements before implementation. RESULTS: Before the first recruitment suspension, NeuroSAFE PROOF was recruiting an average of 9 patients per month. After e-Consent implementation, 63 new patients (4/month) have been enrolled despite a second lockdown, none of whom would have been recruited using the old methods given restrictions on face-to-face consultations. Patients have given positive feedback on the use of the platform. Limited troubleshooting has been required after implementation. CONCLUSION: Remote e-Consent-based recruitment was critical for the continuation of the NeuroSAFE PROOF trial during the COVID-19 pandemic. The described pathway complies with ethical and regulatory guidelines for informed consent, while minimizing face-to-face interactions that increase the risk of COVID-19 transmission. This guide will help researchers integrate e-Consent to ongoing or planned clinical trials while uncertainty about the course of the pandemic continues. TRIAL REGISTRATION: NeuroSAFE PROOF trial NCT03317990 . Registered on 23 October 2017. Regional Ethics Committee reference 17/LO/1978.
引用
- Almeida-Magana R, Maroof H, Grierson J, et al. E-Consent-a guide to maintain recruitment in clinical trials during the COVID-19 pandemic. Trials. 2022. PMID: 35550639. doi:10.1186/s13063-022-06333-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。